Every 10-Q that AYTU BioPharma, Inc. (AYTU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.
Aytu BioPharma reported a sharp year-over-year decline in results for the quarter ended March 31, 2026, as it repositioned around CNS medicines and launched EXXUA. Net revenue fell to $12.4 million from $18.5 million, driven by lower ADHD and pediatric portfolio sales, partly offset by EXXUA contributing $2.4 million. The company swung to a quarterly net loss of $5.6 million from net income of $4.0 million, and posted a nine‑month net loss of $14.2 million versus net income of $6.3 million a year earlier. Cash and cash equivalents were $26.7 million, with operating cash use reduced to $1.1 million for the nine months. Aytu carried $10.4 million on its revolving credit facility and $11.6 million of term loan principal, while reclassifying $26.4 million of derivative warrant liabilities to equity, boosting reported stockholders’ equity to $35.1 million.
Aytu BioPharma reported a weaker quarter as it reshapes around central nervous system medicines. For the three months ended December 31, 2025, net revenue from continuing operations was $15.2 million, down from $16.2 million a year earlier, with six‑month revenue at $29.1 million versus $32.8 million.
The company posted a net loss of $10.6 million for the quarter, compared with net income of $0.8 million in the prior‑year period. Results were heavily affected by an $8.2 million loss on derivative warrant liabilities, while loss from operations widened modestly. Six‑month net loss was $8.6 million, versus income of $2.3 million a year ago.
Cash and cash equivalents were $30.0 million, with positive operating cash flow of $3.1 million for the six months. Debt consisted of a $12.1 million term loan and $9.1 million drawn on a revolving credit facility, alongside $27.3 million of derivative warrant liabilities. The quarter also included the initial EXXUA antidepressant launch, generating $0.2 million of revenue, while the ADHD and pediatric portfolios declined.
Aytu BioPharma reported Q1 fiscal 2026 results showing net income from continuing operations of $1.965 million, driven by a $3.784 million non-cash gain from derivative warrant liabilities. Net revenue was $13.888 million versus $16.574 million a year ago, with the ADHD portfolio contributing $13.156 million. Gross profit was $9.186 million and loss from operations was $1.504 million as operating expenses decreased year over year.
Cash and cash equivalents were $32.630 million and total assets $124.988 million. The revolving credit facility balance was $14.873 million, and term loan debt (net) was $12.304 million. Shares outstanding were 9,911,913 as of September 30, 2025; as of November 1, 2025, common stock outstanding was 10,188,208.
The company anticipates launching EXXUA for major depressive disorder in the second fiscal quarter of 2026. During the quarter, 935,000 prefunded warrants were exercised into common stock. In June 2025, Aytu raised $16.6 million in gross proceeds via common stock and prefunded warrants to support working capital and EXXUA commercialization.